Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting. (18th April 2018)

• Record Type: Journal Article
• Authors: Best, Anne-Laurence; Fajnkuchen, Franck; Nghiem-Buffet, Sylvia; Grenet, Typhaine; Quentel, Gabriel; Delahaye-Mazza, Corinne; Cohen, Salomon Y.; Giocanti-Aurégan, Audrey
• Other Names: Murata Toshinori Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2018(2018)
• Publication Date: 2018-04-18
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2018/4610129
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : Purpose . To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods . A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results . Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μ m. At M12, the mean VA was 63.4 letters (p < 0.0001 ), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μ m (p = 0.0001 ) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55 ). Discussion/Conclusion . Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients.